Working draft — Scientific review: pending | Regulatory review: pending | Not for external clinical or promotional use without independent verification
Back to Prescriber Hub
0
PrescriberLast reviewed: April 2026

Source Control, Claims Governance and Nomenclature

Teach users and the internal team how the education system controls claims, sources and nomenclature.

Learning Objectives

Understand why legacy IB naming has been removed
Know that NWPT-SM32300 is the only approved product name
Separate product-specific data from molecule-level CBD data
Separate licensed evidence from investigational evidence
Classify claims by source quality
Avoid promotional or over-prescriptive language

Core Content

Cannabinoid medicine sits at the intersection of licensed pharmaceuticals, unlicensed Specials, and consumer wellness products.

Without rigorous source control, educational materials risk conflating licensed evidence with investigational claims, or molecule-level data with product-specific data.

This module establishes the governance framework that underpins every page and module in this education system.

Key Takeaways

  • 1Use only NWPT-SM32300 or NWPT-SM32300 as the product name
  • 2Never conflate molecule-level CBD evidence with product-specific NWPT-SM32300 data
  • 3Never extrapolate evidence between routes of administration
  • 4All claims must be traceable to a verified source
  • 5Patient-facing content must be product-agnostic and non-promotional

Case Example

A content writer drafts a patient-facing page stating 'NWPT-SM32300 has been shown to reduce anxiety in clinical trials.' How should this be corrected?

NWPT-SM32300 must not appear on patient-facing pages (product-agnostic rule).

The claim should reference CBD as a molecule, not a specific product.

The evidence level for anxiety is Level 2-3 (emerging), not Level 1 (licensed).

Correct version: 'Some clinical studies have investigated cannabidiol (CBD) for anxiety symptoms. Evidence is emerging but not yet sufficient for regulatory approval in this indication.'

Knowledge Check

Q1. Which product name should be used in all prescriber materials?

Q2. Can topical CBD evidence be used to support oral CBD claims?

Q3. Where should product-specific PK data appear?

Downloadable Tools

Naming-control one-pager

Quick reference for approved product naming conventions

card

Claims-control checklist

Checklist for verifying claims against source hierarchy

checklist

Source register template

Template for tracking all content sources and review dates

template

Tools are provided as templates for clinical practice. Adapt to your clinic's specific requirements.

References

  1. [1]MHRA. The supply of unlicensed medicinal products (specials). MHRA Guidance Note 14.
  2. [2]GMC. Good practice in prescribing and managing medicines and devices. 2024.
  3. [3]NW PharmaTech. NWPT-SM32300 Investigator's Brochure. Internal document.
Module 1: UK Regulatory

This material is educational and non-promotional. It does not constitute medical advice, prescribing advice, or a recommendation to use any medicine. Any use of an unlicensed medicine requires patient-specific clinical justification, informed consent, monitoring, pharmacovigilance and compliance with applicable regulatory requirements.